King Pharm.'s Advertising Suit Against Rival Hits Snag
Saying lost profits and market share King Pharmaceuticals Inc. sustained following the introduction of Zymogenetics Inc.'s competing blood-clotter are not necessarily the result of unfair competition, a federal judge has denied...To view the full article, register now.
Already a subscriber? Click here to view full article